Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Lansoprazole on Neratinib PK in Healthy Subjects
NCT02334501Phase 1Completed
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Aug 2014
- Primary completion
- Oct 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of neratinib in HER2-positive breast cancer, sponsored by Puma Biotechnology, Inc. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration, Area Under the Concentration-Time Curve from Time Zero to Infinity and 1 more. Started Aug 2014; status: completed.
02
Drugs
neratinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT02334501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02334501.